These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 31494328

  • 1. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 2. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 3. Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action.
    Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H.
    Bioconjug Chem; 2016 Sep 21; 27(9):2132-48. PubMed ID: 27494235
    [Abstract] [Full Text] [Related]

  • 4. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z, Wang M, Wang H, Fang L, Gou S.
    Eur J Med Chem; 2020 May 15; 194():112269. PubMed ID: 32248002
    [Abstract] [Full Text] [Related]

  • 5. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.
    Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H.
    Bioorg Med Chem; 2017 Sep 01; 25(17):4686-4700. PubMed ID: 28728896
    [Abstract] [Full Text] [Related]

  • 6. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 7. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
    Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, Huang X, Wang H.
    J Med Chem; 2024 Apr 25; 67(8):6218-6237. PubMed ID: 38573870
    [Abstract] [Full Text] [Related]

  • 8. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
    Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.
    BMC Cancer; 2016 Feb 23; 16():140. PubMed ID: 26906901
    [Abstract] [Full Text] [Related]

  • 9. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 10. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
    Huang X, Li G, Li H, Zhong W, Jiang G, Cai J, Xiong Q, Wu C, Su K, Huang R, Xu S, Liu Z, Wang M, Wang H.
    J Med Chem; 2024 May 23; 67(10):8020-8042. PubMed ID: 38727048
    [Abstract] [Full Text] [Related]

  • 11. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
    Fang L, Qin X, Zhao J, Gou S.
    Inorg Chem; 2019 Feb 04; 58(3):2191-2200. PubMed ID: 30657321
    [Abstract] [Full Text] [Related]

  • 12. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 13. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance.
    Ma J, Li L, Yue K, Li Y, Liu H, Wang PG, Wang C, Wang J, Luo W, Xie S.
    Bioorg Chem; 2020 Jun 12; 99():103768. PubMed ID: 32217375
    [Abstract] [Full Text] [Related]

  • 14. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
    Jin S, Guo Y, Song D, Zhu Z, Zhang Z, Sun Y, Yang T, Guo Z, Wang X.
    Inorg Chem; 2019 May 06; 58(9):6507-6516. PubMed ID: 31013065
    [Abstract] [Full Text] [Related]

  • 15. Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.
    Elias MG, Aputen AD, Fatima S, Mann TJ, Karan S, Mikhael M, de Souza P, Gordon CP, Scott KF, Aldrich-Wright JR.
    Int J Mol Sci; 2024 Jul 28; 25(15):. PubMed ID: 39125821
    [Abstract] [Full Text] [Related]

  • 16. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z, Hu W, Wang Z, Gou S.
    Eur J Med Chem; 2017 Dec 01; 141():211-220. PubMed ID: 29031068
    [Abstract] [Full Text] [Related]

  • 17. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X, Yu Z.
    Chem Commun (Camb); 2018 May 22; 54(42):5369-5372. PubMed ID: 29744485
    [Abstract] [Full Text] [Related]

  • 18. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
    Qin X, Fang L, Chen F, Gou S.
    Eur J Med Chem; 2017 Sep 08; 137():167-175. PubMed ID: 28586717
    [Abstract] [Full Text] [Related]

  • 19. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 20. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.